Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
NVP-AEW541 is an inhibitor of insulin-like growth factor 1 receptor (IGF-1R; IC50 = 0.15 µM in a cell-free assay).1 It is selective for IGF-1R over a panel of 20 kinases but also inhibits the insulin receptor (InsR), VEGFR1, FMS-related tyrosine kinase 3 (FLT3), and tunica interna endothelial cell kinase 2 (Tie2; IC50s = 0.14, 0.6, 0.42, and 0.53 µM, respectively, in cell-free assays). NVP-AEW541 selectively inhibits the autophosphorylation of IGF-1R over InsR, EGFR, PDGFR, c-Kit, and Bcr-Abl in cells (IC50s = 0.086, 2.3, >10, >10, >5, and >10 µM, respectively). It reduces tumor volume in an NWT-21 murine fibrosarcoma model when administered at doses of 20, 30, or 50 mg/kg twice per day.
WARNING This product is not for human or veterinary use.
1. In vivo antitumor activity of NVP-